469 related articles for article (PubMed ID: 24315115)
1. Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure (from the Korean Heart Failure registry).
Park JJ; Choi DJ; Yoon CH; Oh IY; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Yoo BS; Kang SM; Oh BH;
Am J Cardiol; 2014 Feb; 113(3):511-7. PubMed ID: 24315115
[TBL] [Abstract][Full Text] [Related]
2. Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.
Goei D; Hoeks SE; Boersma E; Winkel TA; Dunkelgrun M; Flu WJ; Schouten O; Bax JJ; Poldermans D
Coron Artery Dis; 2009 May; 20(3):219-24. PubMed ID: 19322079
[TBL] [Abstract][Full Text] [Related]
3. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein but not cystatin C predict cardiovascular events in male patients with peripheral artery disease independently of ambulatory pulse pressure.
Skoglund PH; Arpegård J; Ostergren J; Svensson P
Am J Hypertens; 2014 Mar; 27(3):363-71. PubMed ID: 24470529
[TBL] [Abstract][Full Text] [Related]
4. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
[TBL] [Abstract][Full Text] [Related]
5. N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease.
Ndrepepa G; Kastrati A; Braun S; Mehilli J; Niemöller K; von Beckerath N; von Beckerath O; Vogt W; Schömig A
Am J Med; 2006 Apr; 119(4):355.e1-8. PubMed ID: 16564781
[TBL] [Abstract][Full Text] [Related]
6. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial.
Harutyunyan MJ; Mathiasen AB; Winkel P; Gøtze JP; Hansen JF; Hildebrandt P; Jensen GB; Hilden J; Jespersen CM; Kjøller E; Kolmos HJ; Gluud C; Kastrup J;
Scand J Clin Lab Invest; 2011 Feb; 71(1):52-62. PubMed ID: 21108561
[TBL] [Abstract][Full Text] [Related]
7. Probrain natriuretic peptide and C-reactive protein as markers of acute rejection, allograft vasculopathy, and mortality in heart transplantation.
Arora S; Gullestad L; Wergeland R; Simonsen S; Holm T; Hognestad A; Ueland T; Geiran O; Andreassen A
Transplantation; 2007 May; 83(10):1308-15. PubMed ID: 17519779
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score.
Scrutinio D; Ammirati E; Guida P; Passantino A; Raimondo R; Guida V; Sarzi Braga S; Pedretti RF; Lagioia R; Frigerio M; Catanzaro R; Oliva F
Int J Cardiol; 2013 Oct; 168(3):2120-6. PubMed ID: 23395457
[TBL] [Abstract][Full Text] [Related]
9. Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very poor outcome.
Kubler P; Jankowska EA; Majda J; Reczuch K; Banasiak W; Ponikowski P
Int J Cardiol; 2008 Oct; 129(3):373-8. PubMed ID: 18054808
[TBL] [Abstract][Full Text] [Related]
10. [Comparative prognostic value of plasma and urinary N-terminal pro-B-type natriuretic peptide in patients with acute destabilized heart failure].
Manzano-Fernández S; Januzzi JL; Boronat García M; Bonaque-González JC; Muñoz-Esparza C; Albaladejo-Otón MD; Pastor-Pérez FJ; Pastor P; Valdés M; Pascual-Figal DA
Rev Esp Cardiol; 2011 May; 64(5):365-72. PubMed ID: 21397374
[TBL] [Abstract][Full Text] [Related]
11. Risk stratification with the use of serial N-terminal pro-B-type natriuretic peptide measurements during admission and early after discharge in heart failure patients: post hoc analysis of the PRIMA study.
Eurlings LW; Sanders-van Wijk S; van Kraaij DJ; van Kimmenade R; Meeder JG; Kamp O; van Dieijen-Visser MP; Tijssen JG; Brunner-La Rocca HP; Pinto YM
J Card Fail; 2014 Dec; 20(12):881-90. PubMed ID: 25175696
[TBL] [Abstract][Full Text] [Related]
12. Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure.
Michtalik HJ; Yeh HC; Campbell CY; Haq N; Park H; Clarke W; Brotman DJ
Am J Cardiol; 2011 Apr; 107(8):1191-5. PubMed ID: 21296322
[TBL] [Abstract][Full Text] [Related]
13. Risk stratification in stable coronary artery disease: superiority of N-terminal pro B-type natriuretic peptide over high-sensitivity C-reactive protein, gamma-glutamyl transferase, and traditional risk factors.
Bode E; Wuppinger T; Bode T; Alber H; Ulmer H; Pachinger O; Mair J
Coron Artery Dis; 2012 Mar; 23(2):91-7. PubMed ID: 22157356
[TBL] [Abstract][Full Text] [Related]
14. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
15. Usefulness and predictive value of circulating NT-proBNP levels to stratify patients for referral and priority treatment in a specialized outpatient heart failure center.
Amir O; Paz H; Ammar R; Yaniv N; Schliamser JE; Lewis BS
Isr Med Assoc J; 2008 Feb; 10(2):109-12. PubMed ID: 18432021
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease.
Tuñón J; Blanco-Colio L; Cristóbal C; Tarín N; Higueras J; Huelmos A; Alonso J; Egido J; Asensio D; Lorenzo Ó; Mahíllo-Fernández I; Rodríguez-Artalejo F; Farré J; Martín-Ventura JL; López-Bescós L
Am J Cardiol; 2014 Feb; 113(3):434-40. PubMed ID: 24295549
[TBL] [Abstract][Full Text] [Related]
17. Impact of triiodothyronine and N-terminal pro-B-type natriuretic peptide on the long-term survival of critically ill patients with acute heart failure.
Chuang CP; Jong YS; Wu CY; Lo HM
Am J Cardiol; 2014 Mar; 113(5):845-50. PubMed ID: 24406111
[TBL] [Abstract][Full Text] [Related]
18. N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission.
Weber M; Bazzino O; Navarro Estrada JL; Fuselli JJ; Botto F; Perez de Arenaza D; Möllmann H; Nef HN; Elsässer A; Hamm CW
J Am Coll Cardiol; 2008 Mar; 51(12):1188-95. PubMed ID: 18355657
[TBL] [Abstract][Full Text] [Related]
19. [Association between serum NT-proBNP/hs-CRP and acute rejection after heart transplantation].
Yin D; Huang J; Feng L; Feng GX; Hu SS
Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Feb; 37(2):145-8. PubMed ID: 19719993
[TBL] [Abstract][Full Text] [Related]
20. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
